Difference between revisions of "Duloxetine-tranylcypromine"

From Psychiatrienet
Jump to: navigation, search
Line 3: Line 3:
 
| to = tranylcypromine  
 
| to = tranylcypromine  
 
| stop =  
 
| stop =  
{{decrease25p3d}}
+
{{generaldecrease25p3d}}
 
| start =  
 
| start =  
 
{{starttranyl}}
 
{{starttranyl}}

Revision as of 12:58, 20 June 2016

Duloxetine
Type Antidepressant
Group SNRI
links
Medscape Duloxetine
PubChem 60835
PubMed Duloxetine
Kompas (Dutch) Duloxetine
Wikipedia Duloxetine
Tranylcypromine
Type Antidepressant
Group MAO-I
links
Medscape Tranylcypromine
PubChem 5530
PubMed Tranylcypromine
Kompas (Dutch) Tranylcypromine
Wikipedia Tranylcypromine

Switch medication from duloxetine to tranylcypromine.[1] [2]

Nietinrijdenbord.png Stop duloxetine
  • Decrease with about 25% of original dose every 3 days
Eenrichtingbord.png Start tranylcypromine
  • Start tranylcypromine in a low dosage of 20 mg/day for one week.
  • After this week the dosage of tranylcypromine can be increased.
Letopbord.png Cave
Infobord.png More information
  • A wash-out period of two weeks is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.